Teniposide

Teniposide

Teniposide is a chemotherapy drug that is classified as a topoisomerase II inhibitor. It is primarily used in the treatment of cancer, specifically pediatric leukemia and neuroblastoma. Teniposide works by interfering with the growth of cancer cells, which eventually leads to their destruction.

History

Teniposide was first approved by the Food and Drug Administration (FDA) in 1992. It was developed as a semi-synthetic derivative of podophyllotoxin, a compound found in the American Mayapple plant.

Mechanism of Action

Teniposide inhibits the enzyme topoisomerase II, which is essential for DNA replication. By doing so, it prevents the cancer cells from dividing and growing. This leads to cell death and the reduction of the tumor size.

Uses

Teniposide is used in combination with other chemotherapy drugs to treat certain types of cancer. It is most commonly used in the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients. It may also be used in the treatment of neuroblastoma, a type of cancer that often affects children.

Side Effects

Like all chemotherapy drugs, teniposide can cause side effects. These may include nausea, vomiting, hair loss, and low blood cell counts. More serious side effects can include allergic reactions, lung problems, and an increased risk of secondary cancers.

Dosage and Administration

Teniposide is administered intravenously, usually in a hospital or clinic setting. The dosage is determined by the patient's body surface area and the type of cancer being treated.

See Also

• Chemotherapy
• Leukemia
• Neuroblastoma
• Topoisomerase II inhibitors